New data, published in JMIR, demonstrates the value of personalized messaging encouraging flu vaccinations in Dario members with diabetes NEW YORK, May 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the Journal of Medical Internet Research ("JMIR") demonstrating the effectiveness of personalized digital health interventions to drive flu vaccine awareness in Dario members living with ...

iRhythm (IRTC) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Stephanie Zhadkevich - Director of Investor RelationsQuentin Blackford - President, CEO & DirectorDaniel Wilson - CFOAllen Gong - Vice PresidentMacauley Kilbane - Equity Research AssociateSuraj Kalia - Managing DirectorJon Young - DirectorRichard Newitter - Managing Director Conference Call Participants Kallum Titchmarsh - AnalystNone - AnalystNathan Treybeck - AnalystDavid Rescott - Senior Research AnalystDavid Saxon - Senio ...

iRhythm (IRTC) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 afternoon. Thank you for attending the iRhythm Technologies Inc. First Quarter twenty twenty five Earnings Conference Call. My name is Cameron, and I'll be your moderator for today. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. Again, due to the interest of time, we ask that you ask one question and to re queue for any follow-up questions. I would now like to ...

Glaukos (GKOS) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate AffairsThomas Burns - Chairman & CEOThomas Stephan - Vice PresidentJoseph Gilliam - President & COOAllen Gong - Vice PresidentJoanne Wuensch. - Managing DirectorRichard Newitter - Managing DirectorAlex Thurman - Senior VP & CFOAnthony Petrone - Managing DirectorPatrick Wood - Managing Director Conference Call Participants Ryan Zimmerman - Managing Director & Medical Technology AnalystLawre ...

Glaukos (GKOS) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Welcome to the Glycos Corporation First Quarter twenty twenty five Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today, are available at www.glycos.com. As a reminder, all lines are muted until the end of today's presentation, where we will have a question and answer session. This call is being recorded and an archived replay will be made ava ...

An independently validated study highlighted K12 Tutoring’s success in personalized, academic supportReston, VA, April 30, 2025 (GLOBE NEWSWIRE) -- K12 Tutoring, a leading personalized online tutoring service, has earned Level II validation under the Every Student Succeeds Act (ESSA), confirming a strong, evidence-based link between the platform’s use and positive student outcomes. This recognition underscores K12 Tutoring’s role as an effective academic intervention, providing schools and districts with re ...

最近总有人问我："十年后房子会不会像白菜一样便宜？" 这问题搁五年前，我肯定笑话你杞人忧天，但现在我会认真告诉你："有可能，但要看两个关键信号。" 先看一组让人脊背发凉的数据：截至2025年4月，全国商品房待售面积达8.2亿平方米，相当于14亿人每 人"分摊"5.8平方米库存。 更可怕的是，三四线城市库存去化周期普遍超过36个月，意味着即便不卖地不建房，现有房子也够卖3 年。 武汉三环外某楼盘直接降价20%还送车位，郑州南三环公寓单价从1万跌到6000元，降幅达40%。这些 现象背后，是两个正在发酵的"蝴蝶效应"。 更狠的是房产税试点扩围，60个城市对二套房征收0.3%-0.8%的持有税，上海一套1000万的房子每年要 交4.2万税。 持有成本飙升，迫使炒房客抛售，广州某小区二手房挂牌量一年内激增300%。 第一个信号：人口结构剧变，住房需求断崖式下跌 国家统计局数据显示，2025年中国60岁以上人口将突破3亿，占比22%，正式进入深度老龄化社会。这 意味着什么？ 简单算笔账：一个三口之家变成两位老人独居，住房需求直接砍掉三分之一。 更致命的是，年轻人结婚生子意愿持续低迷，2023年全国结婚登记量仅683万对 ...

Company Overview - Merit Medical Systems, Inc. (MMSI) has launched the Ventrax Delivery System, aimed at enhancing precision and control in pulmonary interventions, reflecting the company's commitment to improving procedural efficiency and outcomes in interventional medicine [1][2] Product Details - The Ventrax Delivery System expands MMSI's electrophysiology and cardiac rhythm management (CRM) portfolio, addressing the clinical demand for safer and more reliable pulmonary access technologies [2] - The system facilitates retrograde aortic access for catheter-based procedures, allowing precise placement of diagnostic, mapping, or treatment catheters into the left ventricle through the aorta, improving procedural accuracy [8][9] - Key features include a 95-cm sheath for navigating to critical target zones, a low-profile transition for smooth insertion, and an angled tip for enhanced reach, providing greater control during complex procedures [9] Market Context - The global cardiac rhythm management devices market was estimated at $17.17 billion in 2024, projected to grow at a CAGR of 6.4% from 2025 to 2030, driven by the rising prevalence of cardiovascular diseases and technological innovations [10][11] - The demand for advanced diagnostic tools like the Ventrax Delivery System is expected to rise as lung cancer screening and minimally invasive procedures gain traction [4] Financial Performance - MMSI currently has a market capitalization of $5.44 billion and has surpassed earnings estimates for the last four quarters, delivering an average surprise of 8.1% [5]

Core Viewpoint - HOPE Therapeutics, Inc. has signed a definitive agreement to acquire Dura Medical, enhancing its interventional psychiatry network on Florida's west coast, with Dura being revenue-generating and EBITDA positive [1][9]. Company Overview - HOPE Therapeutics is focused on developing a network of interventional psychiatry clinics that utilize psychedelic medications, including ketamine and Spravato®, combined with Transcranial Magnetic Stimulation (TMS) and other therapies for patients with suicidal depression and related disorders [7]. - NRx Pharmaceuticals, the parent company of HOPE, is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression and chronic pain [8]. Acquisition Details - Dura Medical, founded in 2018, specializes in a precision approach to treating mental health and chronic pain, offering services such as Ketamine Infusion Therapy and TMS [2][9]. - The acquisition is expected to provide comprehensive services to patients and is part of HOPE's strategy to expand its operations in Florida [1][9]. - The intended closing of the acquisition is subject to financial audits, regulatory approvals, and standard closing conditions [6]. Leadership and Mission - Stephen Durand, the founder of Dura Medical, will serve as the Director of Florida Clinic Operations for HOPE, emphasizing the mission to reduce suicide rates and treat over 10,000 individuals by 2026 [4][3]. - The collaboration aims to integrate Dura's commitment to patient care for both civilians and veterans into HOPE's network [5][9]. Services Offered - Dura Medical provides a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and TMS, catering to both veteran and civilian patients [9]. - The clinics utilize advanced interventional psychiatry procedures to address various mental health issues, including depression, suicidality, PTSD, and anxiety [2]. Future Plans - HOPE Therapeutics plans to expand its service offerings and enhance its operational capabilities through the acquisition of Dura Medical and the previously announced Neurospa network [1][9]. - The company is also pursuing the development of NRX-101, an investigational therapy for suicidal treatment-resistant bipolar depression, with plans to file for Accelerated Approval [8][10].